InvestorsHub Logo
Followers 45
Posts 16208
Boards Moderated 0
Alias Born 09/16/2012

Re: jdheart101 post# 598527

Monday, 06/05/2023 9:23:24 AM

Monday, June 05, 2023 9:23:24 AM

Post# of 705403
LOL...This company is so far off the radar you'd think they're actually CIA! ...huh? Hmm.

>>The company is reluctant to talk about its plans for regulatory filings, however, saying in a statement that, while the INDIGO readout has come “well ahead of schedule”, it is still “working to determine filing timelines and adapt the vorasidenib supply capacity.”

“The results of the phase 3 INDIGO trial, meeting both the primary endpoint of progression-free survival and the key secondary endpoint of time to next intervention, presents an opportunity to shift the treatment paradigm for patients with IDH mutant low-grade glioma by potentially delivering the first targeted therapy,” she added.

https://pharmaphorum.com/news/serviers-18bn-agios-deal-delivers-glioma-prospect
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News